Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
Pavord I, Gardiner F, Heaney L, Domingo C, Price R, Pullan A, Oppenheimer J, Brusselle G, Nagase H, Chupp G, Pizzichini E, Bañas-Conejero D, Howarth P. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study. Frontiers In Immunology 2023, 14: 1150162. PMID: 37122713, PMCID: PMC10131245, DOI: 10.3389/fimmu.2023.1150162.Peer-Reviewed Original ResearchConceptsSevere eosinophilic asthmaClinical remissionEosinophilic asthmaRemission definitionsClinical practiceAsthma Control Test scoresBetter ACT scoresProportion of patientsSubset of patientsACT scoreMepolizumab therapyMepolizumab treatmentOral corticosteroidsPrior exacerbationsOC useSevere asthmaBaseline characteristicsExpiratory volumeLung functionRemission outcomesMedical recordsDisease progressionTreatment outcomesRemissionTreatment goalsReal-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study
Chupp G, Heaney L, Price R, Brusselle G, Gardiner F, Raimondi A, Chaudhuri R, Howarth P. Real-World Impact of Mepolizumab on the Oral Corticosteroid Freedom Component of Clinical Remission in Severe Eosinophilic Asthma: International, Prospective REALITI-A Study. Journal Of Allergy And Clinical Immunology 2023, 151: ab20. DOI: 10.1016/j.jaci.2022.12.066.Peer-Reviewed Original Research